Purine nucleoside phosphorylase as enzymatic activator of nucleoside prodrugs
AssigneesThe UAB Research Foundation, Southern Research Institute
InventorsWilliam B. Parker, Eric J. Sorscher
Life of this patent
Estimating the term…
Abstract
A process for inhibiting a mammalian cancerous cell or virally infected cell includes providing a Trichomonas vaginalis purine nucleoside phosphorylase enzyme or a tail mutant purine nucleoside phosphorylase enzyme in proximity to the mammalian cancerous cell or the virally infected cell and exposing the enzyme to a purine nucleoside phosphorylase enzyme cleavable substrate to yield a cytotoxic purine analog. The process includes introducing to the cell a vector containing the phosphorylase enzyme, or a DNA sequence coding for the same and delivering to the cell an effective amount of the substrate such as 9-(β-D-arabinofuranosyl)-2-fluoroadenine (F-araA).
Claims7
A process for inhibiting a mammalian cancerous cell or virally infected cell comprising:
- providing a tail mutant purine nucleoside phosphorylase enzyme having a tail of between 10 and 50 additional amino acid residues and corresponding to a frame shift mutation within a terminal 150 nucleic acid residues associated with a nucleotide sequence associated with a wild type purine nucleoside phosphorylase in proximity to the cancerous mammalian cell or the virally infected cell;
- and
- exposing the enzyme to a cleavable substrate to yield a cytotoxic purine analog.
Dependencies are inferred from the claim text.